No ASX ETF holds Starpharma (SPL) as of 15 Oct 2026. Over the last 3 months it rose 2.7%: on $10,000, +$274. We explain 6 big moves in that time.
About SPL
- SectorHealth Care
- IndustryPharmaceuticals, Biotechnology & Life Sciences
- Size$398.2m
- Held by0 ETFs
- Big moves6 in 3M
Each dot is a move we explain. Tap one, or a row of Why it moved, to see what caused it.
Why it moved
- −8.6%peak −10.3%1 Oct 2026· Management
A board chair and deputy chair appointment announcement appears to have unsettled investors, driving an outsized sell-off beyond what sector weakness alone can explain.
- +4.3%peak +5.8%13 Aug 2026· Stake Change
Multiple directors purchased shares through the recently completed $32 million entitlement offer, signalling strong insider confidence and prompting a positive market re-rating of the stock.
- −5.4%12 Aug 2026· Capital Raise
Starpharma launched a $32 million capital raise, causing dilution and a sharp drop in the stock price.
- −7.5%peak −19.9%11 Aug 2026· Capital Raise
Starpharma's stock fell sharply after completing a $32 million renounceable entitlement offer, with new shares being quoted, causing dilution-driven selling pressure.
- +6.7%peak +8.0%5 Aug 2026· Unknown
SPL.AX rose sharply alongside a broader lift in the ASX healthcare sector, likely driven by a general sector rotation or positive sentiment across health stocks rather than any company-specific news.
- +8.0%28 Jul 2026· Sector Flow
SPL.AX rose strongly alongside a broad rally in Australian healthcare sector stocks, lifting the stock on sector-wide buying momentum.
Held by 0 ETFs
No ETF we track holds SPL directly.
Other Health Care companies
- SHLSonic Healthcare47 ETFs
- RMDResMed44 ETFs
- CSLCSL Limited42 ETFs
- BDXBcal36 ETFs
- CSXCleanspace36 ETFs
- REGRegis Health33 ETFs
- TLXTelix Pharma32 ETFs
- SIGSigma Healthcare31 ETFs
Why did SPL fall 8.6% on 1 Oct 2026?
Starpharma
A board chair and deputy chair appointment announcement appears to have unsettled investors, driving an outsized sell-off beyond what sector weakness alone can explain.
The only company-specific announcement in the window is a Chair/Deputy Chair appointment, which is marked non-market-sensitive and matched only on category — a weak signal. The health sector fell 1.74% and peers fell 1.87%, but SPL dropped 8.05% (over 4x the sector move), meaning sector flow cannot proportionately explain the move. With no news, no earnings, and no other filings, the board change is the most plausible trigger (possibly signalling an unwanted leadership shift or read-through to strategic uncertainty), but the evidence is circumstantial and confidence remains low.
Written by a language model from the evidence below, and it can be wrong. Tell us and we will fix or remove it. General information only, not financial product advice. It does not consider your objectives, finances or needs. Past performance is not a guide to future performance.
Evidence
Company announcements
Sector / macro signals